Lei Yu

Lei Yu

Auto-generated profile, based on publicly available information

Lei Yu

Rush Alzheimer’s Disease Center & Department of Neurological Sciences, Rush University Medical Center, Chicago, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
RWRobert Wilson
Robert Wilson
LYLei Yu
Lei Yu
JTJohn Q. Trojanowski
John Q. Trojanowski
ECEr-Yun Chen
Er-Yun Chen
PBPatricia A. Boyle
Patricia A. Boyle
JSJulie A. Schneider
Julie A. Schneider
Transactive response DNA-binding protein 43 (TDP-43) is the primary protein aggregate in frontotemporal lobar degeneration and amyotrophic lateral sclerosis,1,2 but TDP-43 also forms pathologic aggregates in other proteinopathies such as Alzheimer disease (AD),3 suggesting that it may contribute to cognitive dysfunction in these disorders. Immunoreactivity of TDP-43 is related to older age,4,5 with nearly half of older control participants in a recent study showing evidence of at least mild TDP-43 pathology,5 suggesting that it may play a more prominent role in late-life cognitive decline than previously recognized. However, few studies of TDP-43 have included measurement of cognitive function4,6-9 and these have been based on a single point in time rather than direct assessment of change. In addition, TDP-43 is associated with other neuropathologic conditions, such as AD3,8-10 and hippocampal sclerosis,4,9,10 and it is uncertain whether TDP-43 has an association with cognitive functioning that is independent of these other pathologic processes.9

1 December 2013 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
ALAndrew S. P. Lim
Andrew S. P. Lim
LYLei Yu
Lei Yu
MKMatthew Kowgier
Matthew Kowgier
JSJulie A. Schneider
Julie A. Schneider
ABAron Buchman
Aron Buchman
DBDavid A. Bennett
David A. Bennett
A confluence of genetic, behavioral, and environmental factors contributes to the risk of Alzheimer disease (AD) in elderly people. The apolipoprotein E (APOE [GenBank, 348; OMIM, 107741]) ε4 allele is the most well-established genetic risk factor for AD.1-6 Meanwhile, in older adults, sleep disturbance is common,7 poorer sleep consolidation— the interruption of sleep by repeated awakenings—is associated with worse cognition,8,9 and sleep apnea, which can impair sleep consolidation, is associated with a higher risk of incident mild cognitive impairment and dementia.10 Although the APOE genotype is immutable, many social, environmental, and medical contributors to poor sleep are modifiable.

1 May 2018 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
SNSukriti Nag
Sukriti Nag
LYLei Yu
Lei Yu
PBPatricia A. Boyle
Patricia A. Boyle
SLSue E. Leurgans
Sue E. Leurgans
DBDavid A. Bennett
David A. Bennett
JSJulie A. Schneider
Julie A. Schneider
TDP-43 pathology was investigated in the anterior temporal pole cortex (ATPC) and orbital frontal cortex (OFC), regions often degenerated in frontotemporal lobar degenerations (FTLD), in aging and Alzheimer’s disease (AD). Diagnosis of dementia in the 1160 autopsied participants from 3 studies of community-dwelling elders was based on clinical evaluation and cognitive performance tests which were used to create summary measures of the five cognitive domains. Neuronal and glial TDP-43 cytoplasmic inclusions were quantitated in 8 brain regions by immunohistochemistry, and used in ANOVA and regression analyses. TDP-43 pathology was present in 547 (49.4%) participants in whom ATPC (41.9%) was the most frequently involved neocortical region and in 15.5% of these cases, ATPC was the only neocortical area with TDP-43 pathology suggesting not only that ATPC is involved early by TDP-43 but that ATPC may represent an intermediate stage between mesial temporal lobe involvement by TDP-43 and the last stage with involvement of other neocortical areas. To better study this intermediary neocortical stage, and to integrate with other staging schemes, our previous 3 stage distribution of TDP-43 pathology was revised to a 5 stage distribution scheme with stage 1 showing involvement of the amygdala only; stage 2 showed extension to hippocampus and/or entorhinal cortex; stage 3 showed extension to the ATPC; stage 4 – showed extension to the midtemporal cortex and/or OFC and finally in stage 5, there was extension to the midfrontal cortex. Clinically, cases in stages 2 to 5 had impaired episodic memory, however, stage 3 was distinct from stage 2 since stage 3 cases had significantly increased odds of dementia. The proportion of cases with hippocampal sclerosis increased progressively across the stages with stage 5 showing the largest proportion of hippocampal sclerosis cases. Stage 5 cases differed from other stages by having impairment of semantic memory and perceptual speed, in addition to episodic memory impairment. These data suggest that of the regions studied, TDP-43 pathology in the ATPC is an important early neocortical stage of TDP-43 progression in aging and AD while extension of TDP-43 pathology to the midfrontal cortex is a late stage associated with more severe and global cognitive impairment.

1 November 2020 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
LYLei Yu
Lei Yu
STShinya Tasaki
Shinya Tasaki
JSJulie A. Schneider
Julie A. Schneider
KAKonstantinos Arfanakis
Konstantinos Arfanakis
DDDuc M. Duong
Duc M. Duong
DBDavid A. Bennett
David A. Bennett
Alzheimer disease (AD), cerebrovascular diseases, Lewy body disease, and limbic-predominant age-associated transactive response DNA-binding protein 43 (TDP-43) encephalopathy are primary causes of dementia.1,2 However, these neuropathologic conditions are also commonly observed among elderly individuals who died without dementia or cognitive impairment.3 Data from clinical-pathologic studies show that only a portion of person-specific cognitive decline may be explained by common neuropathologic indices,4 suggesting that many other factors play a role. Although some factors, such as neurodegeneration, are downstream events of neuropathologic conditions, other factors are associated with cognitive decline without working through neuropathologic conditions. Of particular interest is that brains differ in their ability to tolerate various proteinopathies, vessel diseases, and vascular tissue injuries, and this ability is associated with cognitive resilience. Identifying genes and proteins for cognitive resilience (ie, targets that are associated with slowing or preventing cognitive decline regardless of the presence, number, or combination of common neuropathologic conditions) provides a complementary approach to developing new therapeutics for the treatment and prevention of AD and related dementias. Prior research has shown that neural reserve and synaptic proteins may act to maintain late-life cognition, above and beyond the association of neuropathologic conditions with cognition,5-7 while other genes may be associated with a reduction in the deleterious effect of AD pathologic conditions.8 Most of these studies target specific genes and proteins a priori, and it is possible that additional proteins associated with cognitive resilience await discovery.

16 June 2018 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
LYLei Yu
Lei Yu
VPVladislav A. Petyuk
Vladislav A. Petyuk
CGChris Gaiteri
Chris Gaiteri
SMSara Mostafavi
Sara Mostafavi
TYTracy Young‐Pearse
Tracy Young‐Pearse
DBDavid A. Bennett
David A. Bennett

1 November 2015 in Neurobiology of Aging
Verified
Journal Article
Closed access
LYLei Yu
Lei Yu
PBPatricia A. Boyle
Patricia A. Boyle
SNSukriti Nag
Sukriti Nag
SLSue Leurgans
Sue Leurgans
ABAron S. Buchman
Aron S. Buchman
JSJulie A. Schneider
Julie A. Schneider